A major objective of this 3-year competitive renewal proposal is to isolate a subpopulation of mouse lymphocytes that express an opioid receptor. Previous studies from this laboratory have shown that the mouse R1.1 thymoma cell line expresses a kappa1 opioid receptor that is negatively coupled to adenylyl cyclase through a pertussis toxin- sensitive G protein, suggesting that certain cells of the immune system can express opioid receptors. Two approaches will be used to isolate a subpopulation of mouse lymphocytes that express opioid receptors. One approach involves conjugating a 14beta-bromoacetamido derivative of naltrexone to magnetic beads, containing a thiol group. Mouse thymocytes, splenocytes, and enriched T-cell populations will be incubated with the opioid-conjugated beads, followed by washing. Cells, containing an opioid receptor, will bind to the beads, and with the use of magnet, these cells will be separated from cells that lack opioid receptors. The affinity ligand recognizes me, delta, and kappa opioid receptors, and should be useful in isolating cells that contain any type of opioid receptor. The second approach involves the use of a high affinity kappa-selective fluorescent opioid to label the cells, followed by an amplification procedure using phycoerythrin. Both of these procedures have been shown to selectively label the R1.1. and derivative thymoma cell lines, suggesting that these approaches will be successful in isolating a murine lymphocyte subpopulation that expresses opioid receptors. Phenotypic markers will be used to characterize the purified cells and the receptors properties will be determined by binding and second messenger assays. Two commercially available cell lines, derived from the R1.1 thymoma, express a larger number of kappa opioid receptors than the parent R1.1 cells. The potency of -GTP to inhibition agonist binding and the maximal inhibition of adenylyl cyclase activity varies among the three cell lines. Using specific antibodies, the G proteins that are coupled to the kappa opioid receptor in the three cell lines will b e determined. Opioid stimulation of low Km GTPase activity will b e used as a measure of kappa opioid receptor coupling to G proteins. Studies will also determine the correlation between the number of spare receptors and desensitization/downregulation of the kappa opioid receptor. By determining the types of immune cells that express opioid receptors and the factors involved in the coupling of the lymphocytic kappa opioid receptor to adenylyl cyclase, the proposed studies will result in a better understanding of the mechanisms involved in the alteration of immune function by narcotics.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004355-07
Application #
2117146
Study Section
Sociobehavioral Subcommittee (DAAR)
Project Start
1989-08-01
Project End
1996-08-14
Budget Start
1995-07-01
Budget End
1996-08-14
Support Year
7
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Rochester
Department
Pharmacology
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Parkhill, Amy L; Bidlack, Jean M (2006) Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line. Int Immunopharmacol 6:1013-9
Bidlack, Jean M; Khimich, Maxim; Parkhill, Amy L et al. (2006) Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol 1:260-9
Gekker, Genya; Hu, Shuxian; Wentland, Mark P et al. (2004) Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther 309:600-6
Peterson, P K; Gekker, G; Lokensgard, J R et al. (2001) Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes. Biochem Pharmacol 61:1145-51
Bidlack, J M; Abraham, M K (2001) Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression. Adv Exp Med Biol 493:103-10
Martin-Kleiner, I; Bidlack, J M (2001) Chronic opioid treatment of the mouse thymoma cell lines R1.G1 and R1EGO leads to down-regulation of the kappa opioid receptor without desensitization of adenylyl cyclase activity. Int Immunopharmacol 1:13-20
Bidlack, J M (2000) Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 7:719-23
Martin-Kleiner, I; Bidlack, J M (1999) The synthetic kappa-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line. Int J Immunopharmacol 21:133-40
Ignatowski, T A; Bidlack, J M (1999) Differential kappa-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation. J Pharmacol Exp Ther 290:863-70
Ignatowski, T A; Bidlack, J M (1998) Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry. J Pharmacol Exp Ther 284:298-306

Showing the most recent 10 out of 24 publications